Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021

Source :: GlobeNewswire. September 20, 2021
Publication Year :: 2021
Abstract: BOSTON, Sep 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor [...]

Subjects :: Medical research -- Political aspects
Medicine, Experimental -- Political aspects
Tumor proteins -- Political aspects
Clinical trials -- Political aspects
Cancer -- Political aspects
Banking, finance and accounting industries
Business

Tools